Frontiers in immunology · 2026
Identification and validation of an endotoxin tolerance-based prognostic model with therapeutic insights in sepsis.
СтатьяВалидационное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xie Yu, Su Yadong, Qin Yin, Zhang Qiuhong, Liu Jie, Wu Yanlin, Du Ning, Jiang Yu, Liu Gang
Аннотация
BACKGROUND: Sepsis outcomes remain difficult to predict because immune trajectories are heterogeneous and dynamically shift from early activation to immunosuppression. Endotoxin tolerance (ET) in circulating monocytes/macrophages is a key mechanism of sepsis-associated immunosuppression but has not been systematically leveraged for prognostication. We sought to develop and clinically validate an ET-related gene (ETG) signature for short-term mortality risk stratification.
METHOD: Public whole-blood transcriptomic datasets were intersected with curated ET gene sets to derive ETG candidates. An ensemble machine-learning framework (108 model/feature-selection combinations across 12 algorithms) was used to build and rank prognostic models for 28-day mortality; the final parsimonious signature (10 ETGs, including IL4R, ATM, CX3CR1, FCGR1A) informed a risk score. A two-variable nomogram (age + ETG risk score) was constructed. Internal performance was assessed by bootstrapped calibration, time-dependent ROC/AUC at 7, 14, and 28 days, and Harrell's C-index. Experimental validation used a prospective ICU cohort (n=50; 13 survivors, 37 non-survivors). PBMCs were profiled by RT-qPCR and Western blot; CD14+ monocytes were analyzed by flow cytometry for FCGR1A/CD64, CX3CR1, and PD-1. We further explored regulatory context (ceRNA network) and druggability (DGIdb query and molecular docking to CX3CR1, FCGR1A, and TLR5).
RESULTS: The 10-gene ETG signature stratified mortality risk with acceptable discrimination and calibration. AUCs were 0.76 (95% CI 0.69-0.83), 0.78 (0.72-0.83), and 0.73 (0.67-0.78) at 7, 14, and 28 days, respectively; Harrell's C-index was 0.782. The age-integrated nomogram showed close agreement between predicted and observed survival across timepoints. Functional enrichment indicated immune-response pathways enriched in the low-risk group. In the clinical cohort, non-survivors exhibited lower mRNA and protein levels of FCGR1A, TLR5, and CX3CR1 in PBMCs; flow cytometry revealed reduced proportions of FCGR1A+, CX3CR1+, and PD-1+ CD14+ monocytes (p<0.01). The ceRNA analysis highlighted a putative NEAT1/miR-1287-5p/CX3CR1 axis. Docking suggested plausible ligandability of CX3CR1, FCGR1A, and TLR5, nominating candidates such as valproic acid and CGP-52608 for follow-up testing.
CONCLUSION: An ET-anchored, 10-gene signature captures a clinically relevant axis of sepsis-associated immunosuppression and enables short-term mortality risk stratification. Integration with age yields a simple nomogram with stable internal performance. Multilayer validation (transcript, protein, single-cell) supports biological plausibility. Prospective multicenter studies with richer clinical annotation and functional assays are warranted to confirm generalizability and to evaluate ET-guided immunomodulatory strategies.
METHOD: Public whole-blood transcriptomic datasets were intersected with curated ET gene sets to derive ETG candidates. An ensemble machine-learning framework (108 model/feature-selection combinations across 12 algorithms) was used to build and rank prognostic models for 28-day mortality; the final parsimonious signature (10 ETGs, including IL4R, ATM, CX3CR1, FCGR1A) informed a risk score. A two-variable nomogram (age + ETG risk score) was constructed. Internal performance was assessed by bootstrapped calibration, time-dependent ROC/AUC at 7, 14, and 28 days, and Harrell's C-index. Experimental validation used a prospective ICU cohort (n=50; 13 survivors, 37 non-survivors). PBMCs were profiled by RT-qPCR and Western blot; CD14+ monocytes were analyzed by flow cytometry for FCGR1A/CD64, CX3CR1, and PD-1. We further explored regulatory context (ceRNA network) and druggability (DGIdb query and molecular docking to CX3CR1, FCGR1A, and TLR5).
RESULTS: The 10-gene ETG signature stratified mortality risk with acceptable discrimination and calibration. AUCs were 0.76 (95% CI 0.69-0.83), 0.78 (0.72-0.83), and 0.73 (0.67-0.78) at 7, 14, and 28 days, respectively; Harrell's C-index was 0.782. The age-integrated nomogram showed close agreement between predicted and observed survival across timepoints. Functional enrichment indicated immune-response pathways enriched in the low-risk group. In the clinical cohort, non-survivors exhibited lower mRNA and protein levels of FCGR1A, TLR5, and CX3CR1 in PBMCs; flow cytometry revealed reduced proportions of FCGR1A+, CX3CR1+, and PD-1+ CD14+ monocytes (p<0.01). The ceRNA analysis highlighted a putative NEAT1/miR-1287-5p/CX3CR1 axis. Docking suggested plausible ligandability of CX3CR1, FCGR1A, and TLR5, nominating candidates such as valproic acid and CGP-52608 for follow-up testing.
CONCLUSION: An ET-anchored, 10-gene signature captures a clinically relevant axis of sepsis-associated immunosuppression and enables short-term mortality risk stratification. Integration with age yields a simple nomogram with stable internal performance. Multilayer validation (transcript, protein, single-cell) supports biological plausibility. Prospective multicenter studies with richer clinical annotation and functional assays are warranted to confirm generalizability and to evaluate ET-guided immunomodulatory strategies.